<DOC>
	<DOCNO>NCT00012051</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop dividing . Peripheral stem cell transplant may able replace immune cell destroy chemotherapy . Monoclonal antibody , rituximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . It yet know give one drug ( combination chemotherapy ) plus peripheral stem cell transplant effective without monoclonal antibody therapy treat non-Hodgkin 's lymphoma . PURPOSE : This randomized phase III trial study well chemotherapy plus peripheral stem cell transplant without monoclonal antibody therapy work treat patient relapse non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Chemotherapy Peripheral Stem Cell Transplant With Without Monoclonal Antibody Therapy Treating Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare partial complete response rate patient relapse , CD20 positive , aggressive B-cell non-Hodgkin 's lymphoma treat dexamethasone , cisplatin , cytarabine combination etoposide , ifosfamide , methotrexate without rituximab follow carmustine , etoposide , cytarabine , melphalan , autologous peripheral blood stem cell transplantation ( APBSCT ) . - Compare effect APBSCT without rituximab overall event-free survival patient . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center . Patients randomize one two treatment arm . - Arm I : Patients receive DHAP induction chemotherapy comprise dexamethasone orally IV day 1-4 , cisplatin IV continuously 24 hour day 1 , cytarabine IV 3 hour every 12 hour day 2 . Beginning 3-4 week DHAP , patient receive VIM induction chemotherapy comprise etoposide IV 2 hour day 1 , 3 , 5 ; ifosfamide IV 1 hour day 1-5 ; methotrexate IV day 1 5 . Beginning 3-4 week VIM , patient partial complete response DHAP VIM receive second course DHAP ( patient progressive unresponsive disease DHAP responsive disease VIM receive second course VIM ) follow filgrastim ( G-CSF ) subcutaneously begin day 10 continue target number cell collect . - Arm II : Patients receive induction chemotherapy G-CSF arm I . At 1 day last dose chemotherapy course , patient also receive rituximab IV maximum 3 course . At 4-5 week completion last induction chemotherapy course , responsive patient arm receive BEAM conditioning chemotherapy comprise carmustine IV 60 minute day -6 , etoposide IV 60 minute cytarabine IV 30 minute day -5 -2 , melphalan IV 15 minute day -1 . Patients undergo autologous peripheral blood stem cell transplantation day 0 . After transplantation , patient partial remission may undergo radiotherapy nodal sit residual tumor mass . Patients follow every 6 month 3 year annually thereafter . PROJECTED ACCRUAL : A total 296-340 patient ( 148-170 per treatment arm ) accrue study within 4-5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm relapse Bcell nonHodgkin 's lymphoma ( NHL ) Diffuse large cell Bcell lymphoma Grade III follicular centercell lymphoma Primary mediastinal Bcell lymphoma CD20 positive First relapse doxorubicin contain regimen Documented remission least 3 month firstline chemotherapy No EpsteinBarr virus posttransplantation lymphoproliferative disorder No CNS involvement PATIENT CHARACTERISTICS : Age : 18 65 Performance status : WHO 01 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : No hepatic dysfunction Bilirubin le 2.5 time upper limit normal ( ULN ) Transaminases less 2.5 time ULN Renal : No renal dysfunction Creatinine le 2.0 mg/dL OR Creatinine clearance great 40 mL/min Cardiovascular : No severe cardiac dysfunction No New York Heart association class IIIV heart disease Pulmonary : No severe pulmonary dysfunction Vital capacity diffusion capacity least 70 % predict unless related NHL involvement Other : No active uncontrolled infection HIV negative No intolerance exogenous protein administration PRIOR CONCURRENT THERAPY : Biologic therapy : At least 1 month since prior immunotherapy Chemotherapy : See Disease Characteristics At least 1 month since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 1 month since prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
</DOC>